Xue Lin

Center for Biologics Evaluation and Research

Also affiliated with United States Food and Drug Administration

MedicineBiochemistry, Genetics and Molecular BiologyComputer Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma”.

FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0568

N/A

0DataRank · unranked

24 citations

Yvette L. Kasamon, Xue Lin, Zhenzhen Xu, Marc R. Theoret, Tejashri Purohit-Sheth +1 more

FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class–Exposed, Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4181

N/A

0DataRank · unranked

8 citations

Xue Lin, Zhenzhen Xu, Bindu Kanapuru, Marc R. Theoret, Robert Sokolic +2 more